Evidence map›Paper›PMID 33875485›Full record

Trial reportDiabetes care2021

Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial.

Harpreet S Bajaj, Richard M Bergenstal, Andreas Christoffersen, Melanie J Davies, Amoolya Gowda, Joakim Isendahl, Ildiko Lingvay, Peter A Senior, Robert J Silver, Roberto Trevisan and 1 more

Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03922750 (A Trial Comparing NNC0148-0287 C), which is not on this map. Cited by 53 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 6 pooled it
15.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03922750 phase2completednot on this map

A Trial Comparing NNC0148-0287 C (Insulin 287) Versus Insulin Glargine U100, Both in Combination With Metformin, With or Without DPP4 Inhibitors and With or Without SGLT2 Inhibitors, in Basal Insulin Treated Subjects With Type 2 Diabetes Mellitus

TypeinterventionalSponsorNovo Nordisk A/SRan2019 to 2020Enrolled154ConditionsDiabetes Mellitus, Type 2ArmsInsulin icodec, Insulin glargine U100
3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 6 syntheses or guidelines pooled it, 121 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Once-Weekly Insulin IcodecArchives of endocrinology and metabolism · 2023
    Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 5 countries.

Harpreet S BajajLMC Diabetes and Endocrinology, Brampton, Ontario, Canada harpreet.bajaj@lmc.ca.ORCID 0000-0002-1461-1465
Richard M BergenstalInternational Diabetes Center at Park Nicollet, Medical City, Minneapolis, MN.ORCID 0000-0002-9050-5584
Andreas ChristoffersenNovo Nordisk A/S, Søborg, Denmark.
Melanie J DaviesDiabetes Research Centre, University of Leicester, Leicester, U.K.
Amoolya GowdaNovo Nordisk A/S, Søborg, Denmark.
Joakim IsendahlNovo Nordisk A/S, Søborg, Denmark.
Ildiko LingvayUniversity of Texas Southwestern Medical Center, Dallas, TX.ORCID 0000-0001-7006-7401
Peter A SeniorUniversity of Alberta, Edmonton, Alberta, Canada.
Robert J SilverSouthern New Hampshire Diabetes and Endocrinology, Nashua, NH.
Roberto TrevisanAzienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.
Julio RosenstockDallas Diabetes Research Center, Medical City, Dallas, TX.ORCID 0000-0001-8324-3275
Novo Nordisk (Denmark) · DKDallas Diabetes Research Center · USMount Sinai Hospital · CAOspedale Papa Giovanni XXIII · ITPark Nicollet Clinic · USSouthern New Hampshire Medical Center · USThe University of Texas Southwestern Medical Center · USUniversity of Alberta · CAUniversity of Leicester · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveInsulin icodec (icodec) is a novel once-weekly basal insulin analog. This trial investigated two approaches for switching to icodec versus once-daily insulin glargine 100 units/mL (IGlar U100) in people with type 2 diabetes receiving daily basal insulin and one or more oral glucose-lowering medications. RESEARCH DESIGN AND

methodsThis multicenter, open-label, treat-to-target phase 2 trial randomized (1:1:1) eligible basal insulin-treated (total daily dose 10-50 units) people with type 2 diabetes (HbA

resultsEstimated mean TIR during weeks 15 and 16 was 72.9% (icodec LD;

conclusionsSwitching from daily basal insulin to once-weekly icodec was well tolerated and provided effective glycemic control. Loading dose use when switching to once-weekly icodec significantly increased percent TIR during weeks 15 and 16 versus once-daily IGlar U100, without increasing hypoglycemia risk.

Indexed as

Diabetes Mellitus, Type 2Blood GlucoseBlood Glucose Self-MonitoringGlycated HemoglobinHumansHypoglycemic AgentsInsulin GlargineInsulin, Long-ActingBlood GlucoseGlycated HemoglobinHypoglycemic AgentsInsulin Glargineinsulin icodecInsulin, Long-Acting

Identifiers

PMID33875485
PMCPMC8323191
OpenAlexW3152666552

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.